β-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer

Oncogene

Volumn 32, Issue 38, 2013, Pages 4579-4585

  Bakker, E R M ^a   Hoekstra, E ^a   Franken, P F ^a   Helvensteijn, W ^a   Van Deurzen, C H M ^a   Van Veelen, W ^a   Kuipers, E J ^a   Smits, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

catenin; APC; intestinal cancer; mammary tumor

Indexed keywords

APC PROTEIN; BETA CATENIN; CATENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INCIDENCE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; CYST; DESMOID TUMOR; EMBRYO; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HISTOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INTESTINE TUMOR; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ANIMALS; BETA CATENIN; DISEASE MODELS, ANIMAL; FEMALE; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; SIGNAL TRANSDUCTION;

MUS;

EID: 84884595095     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.449     Document Type: Article

References (32)

1. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
2. Albuquerque C, Bakker ER, van Veelen W, Smits R. Colorectal cancers choosing sides. Biochim Biophys Acta 2011; 1816: 219-231.
3. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ et al. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 2002; 11: 1549-1560.
4. Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: A new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999; 5: 1071-1075.
5. Crabtree M, Sieber OM, Lipton L, Hodgson SV, Lamlum H, Thomas HJ et al. Refining the relation between 'first hits' and 'second hits' at the APC locus: The 'loose fit' model and evidence for differences in somatic mutation spectra among patients. Oncogene 2003; 22: 4257-4265.
6. Smits R, Hofland N, Edelmann W, Geugien M, Jagmohan-Changur S, Albuquerque C et al. Somatic Apc mutations are selected upon their capacity to inactivate the beta-catenin downregulating activity. Genes Chromosomes Cancer 2000; 29: 229-239.
7. Leedham SJ, Rodenas-Cuadrado P, Howarth K, Lewis A, Mallappa S, Segditsas S et al. A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut 2012 (e-pub ahead of print 27 January 2012; doi:10.1136/gutjnl-2011-301601).
8. Albuquerque C, Baltazar C, Filipe B, Penha F, Pereira T, Smits R et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer 2010; 49: 746-759.
9. Incassati A, Chandramouli A, Eelkema R, Cowin P. Key signaling nodes in mammary gland development and cancer: Beta-catenin. Breast Cancer Res 2010; 12: 213.
10. Smits R, van der Houven van Oordt W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C et al. Apc1638N: A mouse model for familial adenomatous polyposisassociated desmoid tumors and cutaneous cysts. Gastroenterology 1998; 114: 275-283.
11. Gaspar C, Franken P, Molenaar L, Breukel C, van der Valk M, Smits R et al. A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet 2009; 5: E1000547.
12. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3: 433-438.
13. Nathke I. Cytoskeleton out of the cupboard: Colon cancer and cytoskeletal changes induced by loss of APC. Nat Rev Cancer 2006; 6: 967-974.
14. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009; 137: 623-634.
15. Schneikert J, Brauburger K, Behrens J. APC mutations in colorectal tumours from FAP patients are selected for CtBP-mediated oligomerization of truncated APC. Hum Mol Genet 2011; 20: 3554-3564.
16. Hamada F, Bienz M. The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF. Dev Cell 2004; 7: 677-685.
17. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994; 91: 8969-8973.
18. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001; 105: 533-545.
19. Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM. Genotype-phenotype correlation in murine Apc mutation: Differences in enterocyte migration and response to sulindac. Cancer Res 1999; 59: 353-359.
20. Buchert M, Athineos D, Abud HE, Burke ZD, Faux MC, Samuel MS et al. Genetic dissection of differential signaling threshold requirements for the Wnt/betacatenin pathway in vivo. PLoS Genet 2010; 6: E1000816.
21. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131: 1096-1109.
22. Smits R, Kartheuser A, Jagmohan-Changur S, Leblanc V, Breukel C, de Vries A et al. Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis. Carcinogenesis 1997; 18: 321-327.
23. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Greenson JK, Williams BO et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9721-9730.
24. Shoemaker AR, Luongo C, Moser AR, Marton LJ, Dove WF. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice. Cancer Res 1997; 57: 1999-2006.
25. Obrador-Hevia A, Chin SF, Gonzalez S, Rees J, Vilardell F, Greenson JK et al. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol 2010; 221: 57-67.
26. Fodde R, Tomlinson I. Nuclear beta-catenin expression and Wnt signalling: In defence of the dogma. J Pathol 2010; 221: 239-241.
27. Haigis KM, Dove WF. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. Nat Genet 2003; 33: 33-39.
28. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui Da et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
29. Athineos D, Sansom OJ. Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine. Oncogene 2010; 29: 2585-2590.
30. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999; 18: 5931-5942.
31. Smits R, Kielman MF, Breukel C, Zurcher C, Neufeld K, Jagmohan-Changur S et al. Apc1638T: A mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. Genes Dev 1999; 13: 1309-1321.
32. Lewis A, Davis H, Deheragoda M, Pollard P, Nye E, Jeffery R et al. The C-terminus of Apc does not influence intestinal adenoma development or progression. J Pathol 2012; 226: 73-83.